Neonatal Drug Therapy: The First Frontier of Therapeutics for Children

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 3, 2015, Pages 288-297

  Allegaert, K ^a,b   Anker, J Van Den ^c,d,e,f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXAMETHASONE; DRUG; EXCIPIENT; LOPINAVIR PLUS RITONAVIR; PARACETAMOL; TRAMADOL;

CLINICAL PHARMACOLOGY; DRUG FORMULATION; DRUG RESEARCH; DRUG THERAPY; ENVIRONMENTAL FACTOR; HUMAN; MATURATION; NEONATAL DRUG THERAPY; NEWBORN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; AGE; ANIMAL; CHEMISTRY; CHILD DEVELOPMENT; DOSE CALCULATION; DOSE RESPONSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFANT, NEWBORN, DISEASES; MEDICINAL CHEMISTRY; METABOLISM; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTOR;

AGE FACTORS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHILD DEVELOPMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTORS;

EID: 84940944227     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.166     Document Type: Review

References (64)

1. Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S. & Kauffman, R. E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
2. Allegaert, K. & van den Anker, J. N. Adverse drug reactions in neonates and infants: A population-tailored approach is needed. Br. J. Clin. Pharmacol. (2014); epub ahead of print (doi: 10. 1111/ bcp. 12430).
3. Shinwell, E. S. & Eventov-Friedman, S. Impact of perinatal corticosteroids on neuromotor development and outcome: review of the literature and new meta-analysis. Semin. Fetal Neonatal Med. 14, 164-170 (2009).
4. Saugstad, O. D. & Aune, D. Optimal oxygenation of extremely low birth weight infants: A meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 105, 55-63 (2014).
5. de Wildt, S., Tibboel, D. & Leeder, J. S. Drug metabolism for the paediatrician. Arch. Dis. Child. 99, 1137-1142 (2014).
6. Allegaert, K., van de Velde, M. & van den Anker, J. Neonatal clinical pharmacology. Paediatr Anaesth. 24, 30-38 (2014).
7. Stiers, J. L. & Ward, R. M. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 168, 106-108 (2014).
8. Benjamin, D. K. Jr. et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 296, 1266-1273 (2006).
9. Hampson, L. V., Herold, R., Posch, M., Saperia, J. & Whitehead, A. Bridging the gap: A review of dose investigations in paediatric investigation plans. Br. J. Clin. Pharmacol. 78, 898-907 (2014).
10. Pansieri, C., Bonati, M., Choonara, I. & Jacqz-Aigrain, E. Neonatal drug trials: impact of EU and US paediatric regulations. Arch. Dis. Child. Fetal Neonatal Ed. 99, F438 (2014).
11. Abduljalil, K., Jamei, M., Rostami-Hodjegan, A. & Johnson, T. N. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. AAPS. J. 16, 568-576 (2014).
12. Smits, A., Kulo, A., de Hoon, J. N. & Allegaert, K. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr. Pharm. Des. 18, 3119-3146 (2012).
13. Mooij, M. G., de Koning, B. A., Huijsman, M. L. & de Wildt, S. N. Ontogeny of oral drug absorption processes in children. Expert Opin. Drug Metab. Toxicol. 8, 1293-1303 (2012).
14. Hines, R. N. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int. J. Pharm. 452, 3-7 (2013).
15. Rhodin, M. M. et al. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24, 67-76 (2009).
16. Schreuder, M. F., Bueters, R. R. & Allegaert, K. The interplay between drugs and the kidney in premature neonates. Pediatr. Nephrol. 29, 2083-2091 (2014).
17. Mulla, H. Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr. Drugs 12, 223-233 (2010).
18. Tauris, J., Christensen. E. I., Nykjaer, A., Jacobsen, C., Petersen, C. M. & Ovesen, T. Cubilin and megalin co-localize in the neonatal inner ear. Audiol. Neurootol. 14, 267-278 (2009).
19. Girardi, A. et al. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf. 38, 535-551 (2015).
20. Rakhade, S. N. & Jensen, F. E. Epileptogenesis in the immature brain: emerging mechanisms. Nat. Rev. Neurol. 5, 380-391 (2009).
21. Wang, J., Edginton, A. N., Avant, D. & Burckart, G. J. Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling. J. Clin. Pharmacol. (2015); epub ahead of print (doi: 10. 1002/jcph. 524).
22. Leeder, J. S. & Kearns, G. L. Interpreting pharmacogenetic data in the developing neonate: The challenge of hitting a moving target. Clin. Pharmacol. Ther. 92, 434-436 (2012).
23. Leeder, J. S., Brown, J. T. & Soden, S. E. Individualizing the use of medications in children: making Goldilocks happy. Clin. Pharmacol. Ther. 96, 304-306 (2014).
24. Allegaert, K. et al. Covariates of tramadol disposition in the first months of life. Br. J. Anaesth. 100, 525-532 (2008).
25. Zhu, R. et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J. Clin. Pharmacol. 52, 511-519 (2012).
26. Matic, M. et al. Effect of UGT2B7-900G>A (-842G>A; rs 7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics 15, 1589-1597 (2014).
27. Gaedigk, A., Simon, S. D., Pearce, R. E., Bradford, L. D., Kennedy, M. J. & Leeder, J. S. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-342 (2008).
28. Stamer, U. M., Musshoff, F., Kobilay, M., Madea, B., Hoeft, A. & Stuber, F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 82, 41-47 (2007).
29. Wachman, E. M. et al. Association of OPRM1 and COMT singlenucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 309, 1821-1827 (2013).
30. Leeder, J. S. Developmental pharmacogenetics: A general paradigm for application to neonatal pharmacology and toxicology. Clin. Pharmacol Ther. 86, 678-682 (2009).
31. Haas, D. M. et al. The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. Am. J. Obstet. Gynecol. 206, 447. e17-24 (2012).
32. Allegaert, K. Tailored tools to improve pharmacotherapy in infants. Expert Opin. Drug Metab. Toxicol. 10, 1069-1078 (2014).
33. Wildschut, E. D., de Wildt, S. N., Mathot, R. A., Reiss, I. K, Tibboel, D. & van den Anker, J. Effect of hypothermia and extracorporeal life support on drug disposition in neonates. Semin. Fetal Neonatal Med. 18, 23-27 (2013).
34. Van den Broek, M. P. et al. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: A thermopharmacological approach. Clin. Pharmacokinet. 51, 671-679 (2012).
35. Wildschut, E. D., Ahsman, M. J., Allegaert, K., Mathot, R. A. & Tibboel, D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 36, 2109-2116 (2010).
36. Claus, B. O., Hoste, E. A., Colpaert, K., Robays, H., Decruyenaere, J. & de Waele, J. J. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J. Crit. Care 28, 695-700 (2013).
37. Ince, I. et al. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther. Drug Monit. 34, 381-389 (2012).
38. Shah, R. R. & Smith R. L. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab. Dispos. 43, 400-410 (2015).
39. Blake, M. J., Abdel-Rahman, S. M., Pearce, R. E., Leeder, J. S & Kearns, G. L. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr. Res. 60, 717-726 (2006).
40. Robinson, J. Cochrane in context: probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid. Based Child Health 9, 672-674 (2014).
41. Neu, J. Preterm infant nutrition, gut bacteria, and necrotizing enterocolitis. Curr. Opin. Clin. Nutr. Metab. Care 18, 285-288 (2015).
42. Barrett, E., et al. The neonatal gut harbours distinct bifidobacterial strains. Arch. Dis. Child. Fetal Neonatal Ed. (2015); epub ahead of print (doi: 10. 1136/archdischild-2014-306110).
43. Nunn, A. et al. Estimating the requirement for manipulation of medicines to provide accurate doses for children. Eur. J. Hosp. Pharm. 20, 3-7 (2013).
44. Uppal, N., Yasseen, B., Seto, W. & Parshuram, C. S. Drug formulations that require less than 0. 1 mL of stock solution to prepare doses for infants and children. CMAJ. 183, E246-E248 (2011).
45. Sherwin, C. M., McCaffrey, F., Broadbent, R. S., Reith, D. M. & Medlicott, N. J. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J. Pharm. Pharmacol. 61, 465-471 (2009).
46. Jacqz-Aigrain, E. Drug policy in Europe research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum. Dev. 87(suppl. 1), S27-S30 (2011).
47. Santovena, A., Hernandeze-Paiz, Z. & Farina, J. B. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int. J. Pharm. 423, 360-364 (2012).
48. Hamman, J. & Steenekamp, J. Excipients with specialized functions for effective drug delivery. Expert Opin. Drug Deliv. 9, 219-230 (2012).
49. Turner, M. A. et al. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas. Adv. Drug Deliv. Rev. 73, 89-101 (2014).
50. Nellis, G. et al. Potentially harmful excipients in neonatal medicines: A pan-European observational study. Arch. Dis. Child. (2015); epub ahead of print (doi: 10. 1136/archdischild-2014-307793).
51. Salunke, S., Brandys, B., Giacoia, G. & Tuleu, C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2. The pilot version. Int. J. Pharm. 457, 310-322 (2013).
52. De Cock, R. F. et al. Developmental pharmacokinetics of propylene glycol in preterm and term neonates. Br. J. Clin. Pharmacol. 75, 162-171 (2013).
53. Mulla, H. et al. An observational study of blood concentrations and kinetics of methyl-and propyl-parabens in neonates. Pharm. Res. 32, 1084-1093 (2015).
54. Allegaert, K. et al. Prospective assessment of short-term propylene glycol tolerance in neonates. Arch. Dis. Child. 95, 1054-1058 (2010).
55. McCune, S. K. & Mulugeta, Y. A. Regulatory science needs for neonates: A call for neonatal community collaboration and innovation. Front. Pediatr. 2, 135 (2014).
56. Zhang, B. & Schmidt, B. Do we measure the right end points A systematic review of primary outcomes in recent neonatal randomized clinical trials. J. Pediatr. 138, 76-80 (2001).
57. Schmidt, B. et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 307, 275-282 (2012).
58. U. S. Food and Drug Administration. Accessed 3 May 2015.
59. de Haan, T. R. et al. Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. BMC. Pediatr. 12, 45 (2012).
60. Manolis, E. et al. Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth. 21, 214-221 (2011).
61. Zisowsky, J., Krause, A. & Dingemanse, J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics 2, 364-388 (2010).
62. Bai, J. P., Barrett, J. S., Burckart, G. J., Meibohm, B., Sachs, H. C. & Yao, L. Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. AAPS. J. 15, 447-454 (2013).
63. De Boeck, K. et al. Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). J. Cyst. Fibros. 10 (suppl. 2), S67-S74 (2011).
64. Hoffman, E. P. & Connor, E. M. Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discov. Med. 16, 233-239 (2013).